On the FDA's Fast Track and in phase III testing is the company's BAY 43-9006, a small molecule RAF kinase and VEGF inhibitor that inhibits tumor growth for patients with metastatic renal cell carcinoma (advanced kidney cancer).
Most notably, we completed U.S. and Japanese filings for crizotinib in ALK-positive non-small cell lung cancer and U.S. and EU filings for axitinib in advanced renal cell carcinoma.